TCGA-AN-A04D-01A-21R-A034-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 2
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.640
- G2M_CHECKPOINT+0.550
- MYC_TARGETS_V1+0.450
- MYC_TARGETS_V2+0.400
- DNA_REPAIR+0.360
- SPERMATOGENESIS+0.340
- MITOTIC_SPINDLE+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.200
- OXIDATIVE_PHOSPHORYLATION+0.190
- UV_RESPONSE_UP+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.680
- INTERFERON_GAMMA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.550
- INFLAMMATORY_RESPONSE-0.530
- IL6_JAK_STAT3_SIGNALING-0.500
- ANGIOGENESIS-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- TNFA_SIGNALING_VIA_NFKB-0.440
- COMPLEMENT-0.410
- COAGULATION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG704 | — | — | 0.944 |
| 2 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.939 |
| 3 | SRR8518240 | — | E | 0.938 |
| 4 | SRR8518239 | — | E | 0.937 |
| 5 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.933 |
| 6 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.933 |
| 7 | TCGA-85-8352-01A-31R-2326-07 | — | cohortMD1 | 0.933 |
| 8 | C3L-00993 | — | cohortSQ1 | 0.932 |
| 9 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.932 |
| 10 | C3L-04013 | — | cohortMD1 | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.640 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |